AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 4 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $18.91
- 52-wk high
- $29.23
- High
- $19.09
- 52-wk low
- $12.07
- Low
- $16.15
- Prev close
- $15.48
- Mkt cap
- $12.35B
- Volume
- 27.34M
- Fwd P/E
- 3.7x
- Beta
- -1.24
- P/S
- 3891.3x
- P/B
- 20.8x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -192.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about SMMT filings
Are insiders buying or selling Summit Therapeutics PLC (SMMT) stock?
Neither. Summit Therapeutics PLC (SMMT) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded SMMT recently?
None. No member of Congress disclosed a SMMT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this SMMT smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net buying.
What funds are doing
Buys/Adds (3)
- P7
Point72
$39.0M
added
- MI
Millennium
$31.8M
added
- BA
Balyasny
$17.3M
added
What insiders are doing
Buys (3)
- ZM
Zanganeh Mahkam
$50.0M
bought
- DR
Duggan Robert W
$50.0M
bought
- DR
Duggan Robert W
$1.5M
bought
How top traders are positioned
No tracked top-trader positions in SMMT right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 7.7% below what analysts expected.
Earnings per share
-$0.26 expected
Reports Oct 19, 2026, in 18 days
Estimates as of Sep 30, 2026
EPS expected
-$0.31 to -$0.14
Revenue expected
14 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Jun 2026 |
|---|---|---|
| What came in | ||
| Revenue | $0 | $0 |
| What it spent | ||
| Research and development | $131.1M | $157.7M |
| Sales and admin | $103.1M | $62.8M |
| Total operating expenses | $234.2M | $220.5M |
| What was left | ||
| Operating profit | -$234.2M | -$220.5M |
| Interest on debt | $0 | — |
| Profit before tax | -$231.8M | -$215.7M |
| Net profit | -$231.8M | -$215.7M |
| EBITDA | -$231.8M | -$215.7M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace